FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005104911> ?p ?o ?g. }

• W2005104911 endingPage "711" @default.
• W2005104911 startingPage "706" @default.
• W2005104911 abstract "While an increase in progression free survival time is seen when an angiogenesis inhibitor is used in the treatment of high-relapse rate ovarian cancer, it has little effect on overall survival. A possible cause of treatment-resistance to angiogenesis inhibitors is the growth of stem cells in a hypoxic microenvironment built inside the tumor tissue by angiogenesis inhibition. In this study, we examined the possible suppression of stem cell and cancer stem cell (CSC) expansion by hypoxic cytotoxin, TX-402. TX-402, an analogue of tirapazamine, has been developed as a hypoxia selective prodrug with inhibitory effects of HIF-1 and angiogenesis. We considered TX-402 as a possible molecular-target drug candidate for ovarian cancer due to its inhibition of CSC expansion. In this study, we found that the expressions of HIF-1α and HIF-2α were increased under hypoxia in serous ovarian cancer cell lines. The expressions of HIF-1α and HIF-2α induced under hypoxia were repressed by TX-402 in a dose-dependent manner. Next, we investigated the effects of hypoxia on the expression levels of stem cell factors, Oct4, Nanog, Sox2 and Lin28, and showed that their expressions were induced by hypoxia. It was also observed that the expressions of putative ovarian cancer stem cell markers, CD133 and CD44 were induced under hypoxia. Furthermore, TX-402 was found to dose-dependently inhibit the expressions of CSC markers and stem cell factors. Oct4 expression was repressed by HIF-2α silencing, but not by HIF-1α silencing, indicating that TX-402 may repress the expression of Oct4 by inhibiting HIF-2α. We constructed CaOV3 spheroids as a 3-dimensional hypoxia model, in which the internal hypoxic region contained CSC-like cells expressing Oct4. The internal hypoxic region, which contained Oct4 expressing cells, disappeared following TX-402 treatment. In conclusion, hypoxia promoted the expansion of CSCs expressing CD133 and CD44 accompanied by an increase of stem cell factors. Its inhibition of hypoxia-induced CSC expansion makes TX-402 promising agent usable in combination for ovarian cancer therapy." @default.
• W2005104911 created "2016-06-24" @default.
• W2005104911 creator A5005250738 @default.
• W2005104911 creator A5005728689 @default.
• W2005104911 creator A5022629155 @default.
• W2005104911 creator A5043303385 @default.
• W2005104911 date "2015-02-01" @default.
• W2005104911 modified "2023-10-14" @default.
• W2005104911 title "The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer" @default.
• W2005104911 cites W1965484665 @default.
• W2005104911 cites W1981088384 @default.
• W2005104911 cites W2009886857 @default.
• W2005104911 cites W2017975901 @default.
• W2005104911 cites W2023427658 @default.
• W2005104911 cites W2024206845 @default.
• W2005104911 cites W2026862874 @default.
• W2005104911 cites W2030329983 @default.
• W2005104911 cites W2039075677 @default.
• W2005104911 cites W2040504273 @default.
• W2005104911 cites W2041585886 @default.
• W2005104911 cites W2043457504 @default.
• W2005104911 cites W2067067209 @default.
• W2005104911 cites W2090968329 @default.
• W2005104911 cites W2101176566 @default.
• W2005104911 cites W2105925116 @default.
• W2005104911 cites W2119793842 @default.
• W2005104911 cites W2125987139 @default.
• W2005104911 cites W2155156801 @default.
• W2005104911 cites W2170682201 @default.
• W2005104911 doi "https://doi.org/10.1016/j.bbrc.2015.01.053" @default.
• W2005104911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25619133" @default.
• W2005104911 hasPublicationYear "2015" @default.
• W2005104911 type Work @default.
• W2005104911 sameAs 2005104911 @default.
• W2005104911 citedByCount "20" @default.
• W2005104911 countsByYear W20051049112015 @default.
• W2005104911 countsByYear W20051049112016 @default.
• W2005104911 countsByYear W20051049112017 @default.
• W2005104911 countsByYear W20051049112018 @default.
• W2005104911 countsByYear W20051049112019 @default.
• W2005104911 countsByYear W20051049112021 @default.
• W2005104911 countsByYear W20051049112022 @default.
• W2005104911 countsByYear W20051049112023 @default.
• W2005104911 crossrefType "journal-article" @default.
• W2005104911 hasAuthorship W2005104911A5005250738 @default.
• W2005104911 hasAuthorship W2005104911A5005728689 @default.
• W2005104911 hasAuthorship W2005104911A5022629155 @default.
• W2005104911 hasAuthorship W2005104911A5043303385 @default.
• W2005104911 hasConcept C104317684 @default.
• W2005104911 hasConcept C107459253 @default.
• W2005104911 hasConcept C121608353 @default.
• W2005104911 hasConcept C136302470 @default.
• W2005104911 hasConcept C145103041 @default.
• W2005104911 hasConcept C1491633281 @default.
• W2005104911 hasConcept C178790620 @default.
• W2005104911 hasConcept C185592680 @default.
• W2005104911 hasConcept C207701140 @default.
• W2005104911 hasConcept C2777933648 @default.
• W2005104911 hasConcept C2780394083 @default.
• W2005104911 hasConcept C2780427987 @default.
• W2005104911 hasConcept C2780932548 @default.
• W2005104911 hasConcept C28328180 @default.
• W2005104911 hasConcept C502942594 @default.
• W2005104911 hasConcept C540031477 @default.
• W2005104911 hasConcept C54355233 @default.
• W2005104911 hasConcept C55427017 @default.
• W2005104911 hasConcept C55493867 @default.
• W2005104911 hasConcept C7836513 @default.
• W2005104911 hasConcept C86803240 @default.
• W2005104911 hasConcept C95444343 @default.
• W2005104911 hasConceptScore W2005104911C104317684 @default.
• W2005104911 hasConceptScore W2005104911C107459253 @default.
• W2005104911 hasConceptScore W2005104911C121608353 @default.
• W2005104911 hasConceptScore W2005104911C136302470 @default.
• W2005104911 hasConceptScore W2005104911C145103041 @default.
• W2005104911 hasConceptScore W2005104911C1491633281 @default.
• W2005104911 hasConceptScore W2005104911C178790620 @default.
• W2005104911 hasConceptScore W2005104911C185592680 @default.
• W2005104911 hasConceptScore W2005104911C207701140 @default.
• W2005104911 hasConceptScore W2005104911C2777933648 @default.
• W2005104911 hasConceptScore W2005104911C2780394083 @default.
• W2005104911 hasConceptScore W2005104911C2780427987 @default.
• W2005104911 hasConceptScore W2005104911C2780932548 @default.
• W2005104911 hasConceptScore W2005104911C28328180 @default.
• W2005104911 hasConceptScore W2005104911C502942594 @default.
• W2005104911 hasConceptScore W2005104911C540031477 @default.
• W2005104911 hasConceptScore W2005104911C54355233 @default.
• W2005104911 hasConceptScore W2005104911C55427017 @default.
• W2005104911 hasConceptScore W2005104911C55493867 @default.
• W2005104911 hasConceptScore W2005104911C7836513 @default.
• W2005104911 hasConceptScore W2005104911C86803240 @default.
• W2005104911 hasConceptScore W2005104911C95444343 @default.
• W2005104911 hasIssue "4" @default.
• W2005104911 hasLocation W20051049111 @default.
• W2005104911 hasLocation W20051049112 @default.
• W2005104911 hasOpenAccess W2005104911 @default.
• W2005104911 hasPrimaryLocation W20051049111 @default.
• W2005104911 hasRelatedWork W174417628 @default.

• next